Henry J. Fuchs
2012
In 2012, Henry J. Fuchs earned a total compensation of $2.8M as Executive Vice President & Chief Medical Officer at BioMarin Pharmaceutical, a 53% decrease compared to previous year.
Compensation breakdown
| Bonus | $100,000 |
|---|---|
| Non-Equity Incentive Plan | $282,920 |
| Option Awards | $1,008,600 |
| Salary | $466,400 |
| Stock Awards | $899,040 |
| Other | $5,190 |
| Total | $2,762,150 |
Fuchs received $1M in option awards, accounting for 37% of the total pay in 2012.
Fuchs also received $100K in bonus, $282.9K in non-equity incentive plan, $466.4K in salary, $899K in stock awards and $5.2K in other compensation.
Rankings
In 2012, Henry J. Fuchs' compensation ranked 2,541st out of 11,487 executives tracked by ExecPay. In other words, Fuchs earned more than 77.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,541 out of 11,487 | 78th |
Division Manufacturing | 892 out of 4,253 | 79th |
Major group Chemicals And Allied Products | 204 out of 1,203 | 83rd |
Industry group Drugs | 121 out of 925 | 87th |
Industry Pharmaceutical Preparations | 98 out of 700 | 86th |
Source: SEC filing on April 23, 2015.
Fuchs' colleagues
We found four more compensation records of executives who worked with Henry J. Fuchs at BioMarin Pharmaceutical in 2012.
2012
Daniel Spiegelman
BioMarin Pharmaceutical
Chief Financial Officer
2012
Jean-Jacques Bienaim
BioMarin Pharmaceutical
Chief Executive Officer
2012
Jeff Ajer
BioMarin Pharmaceutical
Senior Vice President, Chief Commercial Officer
2012
Robert Baffi
BioMarin Pharmaceutical
Executive Vice President, Technical Operations
News
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2021 pay rises 1% to $18M
April 12, 2022
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2020 pay slips 2% to $18M
April 13, 2021
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2019 pay rises 18% to $18M
April 14, 2020
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2018 pay slips 2% to $16M
April 23, 2019